Promegestone
Promegestone, sold under the brand name Surgestone, is a progestin medication which is used in menopausal hormone therapy and in the treatment of gynecological disorders. It is taken by mouth.
Clinical data | |
---|---|
Trade names | Surgestone |
Other names | PMG; R-5020; RU-5020; 17α,21-Dimethyl-δ9-19-norprogesterone; 17α,21-Dimethyl-19-norpregna-4,9-diene-3,20-dione |
Routes of administration | By mouth |
Drug class | Progestogen; Progestin |
ATC code | |
Pharmacokinetic data | |
Protein binding | To albumin |
Metabolism | Liver (hydroxylation) |
Metabolites | • Trimegestone |
Elimination half-life | Promegestone: ? Trimegestone: 13.8–15.6 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.207.681 |
Chemical and physical data | |
Formula | C22H30O2 |
Molar mass | 326.480 g·mol−1 |
3D model (JSmol) | |
| |
|
Side effects of promegestone include menstrual irregularities among others. Promegestone is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. It has weak antiandrogenic, glucocorticoid, and antimineralocorticoid activity and no other important hormonal activity. The medication is largely a prodrug of trimegestone.
Promegestone was first described in 1973 and was introduced for medical use in France in 1983. It has only been marketed in a few countries, including France, Portugal, Tunisia, and Argentina. In addition to its use as a medication, promegestone has been widely used in scientific research as a radioligand of the progesterone receptor.